| P2093 | author name string | Soichiro Miura | |
| | Masaki Kitajima | |
| | Tsuneo Takenaka | |
| P2860 | cites work | Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. | Q54846617 |
| | Adult polycystic liver presenting with progressive hepatic failure | Q69753010 |
| | Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease | Q29037884 |
| | Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. | Q33783730 |
| | Angiotensin blockade in late autosomal dominant polycystic kidney disease | Q34836649 |
| | New advances in evaluation and management of patients with polycystic liver disease | Q36310072 |
| | Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease | Q38737946 |
| | Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? | Q40386706 |
| | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease. | Q42368835 |
| | Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. | Q45914643 |
| | Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial | Q46081472 |
| | Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target | Q47662845 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | polycystic liver disease | Q246002 |
| P304 | page(s) | 70-73 | |
| P577 | publication date | 2019-06-13 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | The management of polycystic liver disease by tolvaptan | |
| P478 | volume | 26 | |